{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"institution":[{"name":"bioRxiv"}],"indexed":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T11:09:36Z","timestamp":1779448176240,"version":"3.53.1"},"posted":{"date-parts":[[2026,2,7]]},"group-title":"Cancer Biology","reference-count":51,"publisher":"openRxiv","license":[{"start":{"date-parts":[[2026,2,7]],"date-time":"2026-02-07T00:00:00Z","timestamp":1770422400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"JSPS KAKENHI Grant-in-Aid for Scientific Research","award":["25K11676"],"award-info":[{"award-number":["25K11676"]}]},{"name":"Intramural program of the US National Cancer Institute, NIH, Bethesda, Maryland","award":["Z01-BC-006150"],"award-info":[{"award-number":["Z01-BC-006150"]}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"accepted":{"date-parts":[[2026,5,19]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                <jats:p>\n                  Proteins belonging to the Schlafen family are interferon-inducible and participate in the regulation of antiviral responses, immune signaling and proteotoxic stress. SLFN11 also kills cells with replicative damage, serving as a predictive biomarker for chemotherapeutic response. Here we examined SLFN11 expression and significance in multiple myeloma (MM). The TCGA and MMRF CoMMpass datasets were analyzed for\n                  <jats:italic>SLFN11<\/jats:italic>\n                  expression. Bone marrow and cell lines samples were analyzed for SLFN11 protein. SLFN11-knockout MM cell lines were used to explore how SLFN11 affects bortezomib response. Retrospective analysis of the HOVON-65\/GMMG-HD4 phase III trial (n=327) assessed clinical relevance.\n                  <jats:italic>SLFN11<\/jats:italic>\n                  is consistently highly expressed across MM subtypes (except CD1 and MAF\/MAFB) and in normal plasma cells, and its expression strongly correlates with super-enhancer-driven plasma cell transcriptional programs. CD138-positive normal and myeloma plasma cells retain\n                  <jats:italic>SLFN11<\/jats:italic>\n                  expression even when proliferative activity (\n                  <jats:italic>MKI67<\/jats:italic>\n                  \/Ki-67) increases with disease progression. Bortezomib, a first-line MM treatment, induces SLFN11 nucleolar translocation with suppression of ribosomal RNA synthesis. Knocking out SLFN11 in MM cells enhances bortezomib sensitivity and exatecan resistance, supporting SLFN11\u2019s protective role in proteotoxic stress and sensitizing role in replication stress. In the HOVON-65\/GMMG-HD4 trial,\n                  <jats:italic>SLFN11<\/jats:italic>\n                  -low patients showed selective benefit from bortezomib-based therapy, suggesting that\n                  <jats:italic>SLFN11<\/jats:italic>\n                  expression may guide therapeutic stratification in MM.\n                <\/jats:p>\n                <jats:sec>\n                  <jats:title>Significance<\/jats:title>\n                  <jats:p>SLFN11 is highly expressed in normal and malignant plasma cells. Bortezomib induces SLFN11 nucleolar translocation, suppressing ribosomal RNA synthesis and global translation. SLFN11 confers bortezomib resistance while sensitizing to topoisomerase I inhibitors. Clinical analysis supports that low SLFN11 expression predicts bortezomib benefit, providing a mechanistic basis for SLFN11-guided therapeutic stratification.<\/jats:p>\n                <\/jats:sec>","DOI":"10.64898\/2026.02.06.704297","type":"posted-content","created":{"date-parts":[[2026,2,8]],"date-time":"2026-02-08T00:20:24Z","timestamp":1770510024000},"source":"Crossref","is-referenced-by-count":0,"title":["Schlafen 11 (SLFN11) overexpression in multiple myeloma and nucleolar translocation in response to bortezomib"],"prefix":"10.64898","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1582-0282","authenticated-orcid":false,"given":"Yasuhiro","family":"Arakawa","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH"},{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"},{"name":"Department of Clinical Pharmacology and Therapeutics, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daiki","family":"Taniyama","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuhito","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shingo","family":"Yano","sequence":"additional","affiliation":[{"name":"Division of Clinical Oncology and Hematology, Department of Internal Medicine, The Jikei University School of Medicine, Tokyo, Japan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Pommier","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Pharmacology and Developmental Therapeutics Branch, Center for Cancer Research, NCI, NIH"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"54368","reference":[{"key":"2026052203551147000_2026.02.06.704297v2.1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2022.0003"},{"key":"2026052203551147000_2026.02.06.704297v2.2","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-11-013458"},{"key":"2026052203551147000_2026.02.06.704297v2.3","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01277"},{"key":"2026052203551147000_2026.02.06.704297v2.4","doi-asserted-by":"publisher","DOI":"10.1038\/s41588-024-01853-0"},{"key":"2026052203551147000_2026.02.06.704297v2.5","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/ejh.13840","article-title":"Treatment horizon in multiple myeloma","volume":"109","year":"2022","journal-title":"Eur J Haematol"},{"key":"2026052203551147000_2026.02.06.704297v2.6","doi-asserted-by":"crossref","unstructured":"Jo U , Pommier Y . Structural, molecular, and functional insights into Schlafen proteins. Experimental & Molecular Medicine 2022","DOI":"10.1038\/s12276-022-00794-0"},{"key":"2026052203551147000_2026.02.06.704297v2.7","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2019.05.009"},{"key":"2026052203551147000_2026.02.06.704297v2.8","doi-asserted-by":"publisher","DOI":"10.1126\/science.adh7950"},{"key":"2026052203551147000_2026.02.06.704297v2.9","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2025.01.008"},{"key":"2026052203551147000_2026.02.06.704297v2.10","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15338"},{"key":"2026052203551147000_2026.02.06.704297v2.11","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.Mct-22-0552"},{"key":"2026052203551147000_2026.02.06.704297v2.12","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.12266"},{"key":"2026052203551147000_2026.02.06.704297v2.13","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01364-3"},{"key":"2026052203551147000_2026.02.06.704297v2.14","doi-asserted-by":"publisher","DOI":"10.1111\/cas.15207"},{"key":"2026052203551147000_2026.02.06.704297v2.15","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01560-1"},{"key":"2026052203551147000_2026.02.06.704297v2.16","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-021-01476-w"},{"key":"2026052203551147000_2026.02.06.704297v2.17","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1205943109"},{"key":"2026052203551147000_2026.02.06.704297v2.18","doi-asserted-by":"crossref","first-page":"103173","DOI":"10.1016\/j.isci.2021.103173","article-title":"Schlafen 11 expression in human acute leukemia cells with gain-of-function mutations in the interferon-JAK signaling pathway","volume":"24","year":"2021","journal-title":"iScience"},{"key":"2026052203551147000_2026.02.06.704297v2.19","doi-asserted-by":"crossref","unstructured":"Kaczorowski M , Ylaya K , Chlopek M , Taniyama D , Pommier Y , Lasota J , et al. Immunohistochemical Evaluation of Schlafen 11 (SLFN11) Expression in Cancer in the Search of Biomarker-Informed Treatment Targets: A Study of 127 Entities Represented by 6658 Tumors. Am J Surg Pathol 2024","DOI":"10.1097\/PAS.0000000000002299"},{"key":"2026052203551147000_2026.02.06.704297v2.20","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-14-2112"},{"key":"2026052203551147000_2026.02.06.704297v2.21","doi-asserted-by":"publisher","DOI":"10.1038\/nature11433"},{"key":"2026052203551147000_2026.02.06.704297v2.22","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-20-2694"},{"key":"2026052203551147000_2026.02.06.704297v2.23","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2004.05205.x"},{"key":"2026052203551147000_2026.02.06.704297v2.24","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-09-113092"},{"key":"2026052203551147000_2026.02.06.704297v2.25","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0550-z"},{"key":"2026052203551147000_2026.02.06.704297v2.26","doi-asserted-by":"publisher","DOI":"10.1038\/s41587-020-0546-8"},{"key":"2026052203551147000_2026.02.06.704297v2.27","doi-asserted-by":"publisher","DOI":"10.1093\/bioinformatics\/btac076"},{"key":"2026052203551147000_2026.02.06.704297v2.28","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2018.03.033"},{"key":"2026052203551147000_2026.02.06.704297v2.29","doi-asserted-by":"crossref","unstructured":"Jo U , Murai Y , Takebe N , Thomas A , Pommier Y . Precision Oncology with Drugs Targeting the Replication Stress, ATR, and Schlafen 11. Cancers (Basel) 2021;13","DOI":"10.3390\/cancers13184601"},{"key":"2026052203551147000_2026.02.06.704297v2.30","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(09)70262-1"},{"key":"2026052203551147000_2026.02.06.704297v2.31","doi-asserted-by":"publisher","DOI":"10.1111\/j.1600-0609.2007.00915.x"},{"key":"2026052203551147000_2026.02.06.704297v2.32","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2006-07-037077"},{"key":"2026052203551147000_2026.02.06.704297v2.33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1016\/j.clml.2017.09.010","article-title":"Cellular Proliferation by Multiplex Immunohistochemistry Identifies High-Risk Multiple Myeloma in Newly Diagnosed, Treatment-Naive Patients","volume":"17","year":"2017","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2026052203551147000_2026.02.06.704297v2.34","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-021-01234-0"},{"key":"2026052203551147000_2026.02.06.704297v2.35","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1038\/s41408-021-00421-7","article-title":"Myeloma-specific superenhancers affect genes of biological and clinical relevance in myeloma","volume":"11","year":"2021","journal-title":"Blood Cancer J"},{"key":"2026052203551147000_2026.02.06.704297v2.36","doi-asserted-by":"crossref","first-page":"6810","DOI":"10.1038\/s41467-024-50910-z","article-title":"Super enhancer acquisition drives expression of oncogenic PPP1R15B that regulates protein homeostasis in multiple myeloma","volume":"15","year":"2024","journal-title":"Nat Commun"},{"key":"2026052203551147000_2026.02.06.704297v2.37","doi-asserted-by":"crossref","first-page":"104076","DOI":"10.1016\/j.xpro.2025.104076","article-title":"Protocol to set up the CellMinerCDB pharmacogenomics analysis web application with custom cell line data","volume":"6","year":"2025","journal-title":"STAR Protoc"},{"key":"2026052203551147000_2026.02.06.704297v2.38","doi-asserted-by":"crossref","first-page":"109781","DOI":"10.1016\/j.isci.2024.109781","article-title":"Sarcoma_CellminerCDB: A tool to interrogate the genomic and functional characteristics of a comprehensive collection of sarcoma cell lines","volume":"27","year":"2024","journal-title":"iScience"},{"key":"2026052203551147000_2026.02.06.704297v2.39","doi-asserted-by":"publisher","DOI":"10.1016\/j.molcel.2018.01.012"},{"key":"2026052203551147000_2026.02.06.704297v2.40","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2009-12-261032"},{"key":"2026052203551147000_2026.02.06.704297v2.41","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1038\/s41467-018-05348-5","article-title":"Predicting treatment benefit in multiple myeloma through simulation of alternative treatment effects","volume":"9","year":"2018","journal-title":"Nat Commun"},{"key":"2026052203551147000_2026.02.06.704297v2.42","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.39.6820"},{"key":"2026052203551147000_2026.02.06.704297v2.43","doi-asserted-by":"publisher","DOI":"10.1016\/j.jtho.2020.01.012"},{"key":"2026052203551147000_2026.02.06.704297v2.44","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1038\/s43018-023-00550-x","article-title":"Genome-scale functional genomics identify genes preferentially essential for multiple myeloma cells compared to other neoplasias","volume":"4","year":"2023","journal-title":"Nat Cancer"},{"key":"2026052203551147000_2026.02.06.704297v2.45","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-020-01202-y"},{"key":"2026052203551147000_2026.02.06.704297v2.46","doi-asserted-by":"publisher","DOI":"10.15252\/embr.201540964"},{"key":"2026052203551147000_2026.02.06.704297v2.47","doi-asserted-by":"crossref","first-page":"1525733","DOI":"10.3389\/fphar.2025.1525733","article-title":"Uncovering potential targets for antibody-drug conjugates in the treatment of gynecologic malignancies","volume":"16","year":"2025","journal-title":"Front Pharmacol"},{"key":"2026052203551147000_2026.02.06.704297v2.48","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-19-1089"},{"key":"2026052203551147000_2026.02.06.704297v2.49","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403407"},{"key":"2026052203551147000_2026.02.06.704297v2.50","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1056\/NEJMe2406799","article-title":"A Belantamab Mafodotin Revival in Multiple Myeloma Therapy","volume":"391","year":"2024","journal-title":"N Engl J Med"},{"key":"2026052203551147000_2026.02.06.704297v2.51","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2018024794"}],"container-title":[],"original-title":[],"link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.64898\/2026.02.06.704297","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,22]],"date-time":"2026-05-22T10:55:19Z","timestamp":1779447319000},"score":1,"resource":{"primary":{"URL":"http:\/\/biorxiv.org\/lookup\/doi\/10.64898\/2026.02.06.704297"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2,7]]},"references-count":51,"URL":"https:\/\/doi.org\/10.64898\/2026.02.06.704297","relation":{},"subject":[],"published":{"date-parts":[[2026,2,7]]},"subtype":"preprint"}}